Home / Resources / JP Morgan Post-Conference Report

JP Morgan Post-Conference Report

Report
商業化支援サービス
Banner with text Bringing the future of healthcare into focus overlayed.

The highlights from the most influential summit of the year. This report collates the daily presentation highlights from the conference in a single destination.

Related products
Analyst visualizing the drug development process on screen
Biomedtracker
医薬品開発パイプラインのリアルタイム追跡と分析
Generic Drug Manufacturing
Generics Bulletin
グローバルジェネリック医薬品、バイオシミラー、付加価値のある医薬品業界に関する他の追随を許さないニュースと分析
KOL thought leader interview
In Vivo
ライフサイエンスの意思決定者のためのインタビュー、分析、重要な洞察

Related resources

PDF preview of the Biomedtracker Meddevicetracker Q4 2023 Outlook Report.
FEB 01, 2024
Report
商業化支援サービス

Biomedtracker / Meddevicetracker Q4 2023 Outlook Report

Discover anticipated Q4 2023 catalysts: 32 drugs, devices, diagnostics, and deals. For each, assess Phase/PDUFA success likelihood and overall Likelihood of Approval (LOA) based on phase, drug class, and disease.

JP Morgan announcement for Citeline where exclusive insights will be shared.
JAN 08, 2024
Press Release
商業化支援サービス

Citeline to Share Exclusive Insights from 42nd Annual J.P. Morgan Healthcare Conference

Citeline will offer exclusive access to insights from the 42nd Annual J.P. Morgan Healthcare Conference (JPM) Jan. 8–11, 2024 in San Francisco.

Q3 2023 Outlook Report_resource-card-thumbnail
JUL 01, 2023
Report
商業化支援サービス

Q3 2023 Pharma Outlook Report

In this report, we cover catalysts from 29 drugs, devices, diagnostics, and deals expected to occur in Q3 2023.

View more